Recombination of nucleic acid library members
CA 2489595 C · Owner: Takeda Pharmaceutical Company Limited · Inventors: Hufton, Simon E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides, inter alia, a method of preparing a nucleic acid sequence that encodes a polypeptide that is displayed on a heterologous cell surface. The generally includes recombining a donor nucleic acid and an acceptor nucleic acid to form a recombined nucleic acid that encodes a polypeptide that is displayed. The recombination reaction is typically an in vivo reaction, in that at least the resolution of recombination intermediates occurs within a cell. Both site-specific recombination and homologous recombination can be used.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 16, 2003 and granted May 28, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.